[{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International and Prevacus Provide Development Update on its Potential Concussion and Nieman Picks Drug Candidates","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Announces U.S. FDA Clearance of First Investigational New Drug Application for RLS-0071","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RLS-0071","moa":"Inflammatory cascade","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Imperial College London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Imperial College London"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NMT-cP12","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NeoMatrix Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeoMatrix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoMatrix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Xeno-Skin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"XenoTherapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XenoTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XenoTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions Files IND for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell\u00ae","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Doses First Subject in Phase 1 Healthy Volunteers Study of RLS-0071","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Conducts Phase I Study of Rls-0071 in Acute Lung Damage from Covid-19 Pneumonia in Normal Healthy Volunteers","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Altasciences Company Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Not Applicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Files Septic Shock Treatment Patent for Veyonda\u00ae","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Idronoxil","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071 to Include Three Multiple-Ascending Dose Cohorts","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"The Virginia Catalyst","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"ReAlta Life Sciences Receives $3.2M Grant from Virginia Catalyst to Accelerate Trial for the Treatment of Acute Lung Injury Due to COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Funding","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ The Virginia Catalyst","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ The Virginia Catalyst"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Advanced Technology International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pinteon Therapeutics Announces $3M Award from Advanced Technology International to Support Phase 1 Study of PNT001","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Funding","leadProduct":"PNT001","moa":"Cis-pT231 tau","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Advanced Technology International","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Advanced Technology International"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage\u2019s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Transplant Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"RenovaCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovaCare Update Clinical Trial for the SkinGun, CellMist System Wound Healing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tissue-specific pluripotent cells","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RenovaCare","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray Suspension","sponsorNew":"RenovaCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RenovaCare \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International Completes IND-enabling Studies, Submits Investigator\u2019s Brochure for Phase 1 Clinical Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation\u2019s BIO 300 Receives Fast Track Designation from FDA","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Erase PTSD","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Erase PTSD","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Erase PTSD"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Legend Brett Favre and Odyssey Health, Inc. Involved with Human Trials of First Drug Treatment for Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$5.1 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. Department of Defense Awards $5.1 Million to Humanetics Corporation for Continued Development of Radiation Countermeasure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Genistein","moa":"PTK","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Humanetics \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health Completes Safety Evaluation of Cohort II for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Reports Positive Phase 1 Data for HY-004, a Proprietary Tranexamic Acid Oral Mouth Rinse for Bleeding Related to Dental Procedures","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Avance Clinical"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Presents at the 68th Annual International Radiation Research Society Meeting","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Genistein","moa":"PTK","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Not Applicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"STP705","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluris PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Funding","leadProduct":"PLX-R18","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pluri \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics to Acquire Odyssey Health\u2019s Neurological Drug Technology Pipeline Including Concussion Drug Candidate","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Completes Acquisition of Odyssey Health\u2019s Neurological Assets","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Announces Pricing of Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ ThinkEquity"},{"orgOrder":0,"company":"Oragenics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Announces Closing of Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ ThinkEquity"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Odyssey Health"},{"orgOrder":0,"company":"Oragenics","sponsor":"Avance Clinical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Avance Clinical"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Exercises Option to Fund $1.4 Million for Pluri\u2019s Acute Radiation Syndrome Contract","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics, Inc. Announces Proposed Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics, Inc. Announces Pricing of Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics, Inc. Announces Closing of Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
